Collegium to Report Fourth Quarter and Full-Year 2025 Financial Results on February 26, 2026
Rhea-AI Summary
Collegium (Nasdaq: COLL) will report fourth-quarter and full-year 2025 financial results before the market opens on Thursday, February 26, 2026. The company will host a live conference call and webcast at 8:00 a.m. ET the same day. An audio webcast will be available on the Investors section of the company website and replayable approximately two hours after the event.
Positive
- None.
Negative
- None.
News Market Reaction – COLL
In the Feb 12 session, COLL gained 0.31%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 15 | Medical conference data | Positive | +0.7% | Real‑world data posters on Jornay PM at APSARD 2026 conference. |
| Jan 8 | Guidance and update | Positive | +3.2% | Issued 2026 revenue and EBITDA guidance plus business update and credit facility detail. |
| Dec 30 | Debt refinancing | Positive | -4.8% | Closed $980M syndicated credit facility and refinanced prior term loan. |
| Nov 12 | Investor conferences | Neutral | +5.6% | Announced participation in multiple late‑2025 investor conferences with webcasts. |
| Nov 6 | Earnings and guidance | Positive | +13.4% | Reported record Q3 2025 results and raised full‑year 2025 guidance. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news tied to earnings, guidance, and growth initiatives has often seen positive price alignment, with debt refinancing the main recent divergence.
Over the last few months, Collegium has reported record Q3 2025 results with raised 2025 guidance, provided detailed 2026 revenue and EBITDA guidance, and closed a large syndicated credit facility. The stock reacted positively to earnings and guidance updates, including a 13.42% move after Q3 results and 3.22% after 2026 guidance, while the refinancing announcement coincided with a 4.75% decline. Conference participation and real‑world data presentations also drew modest positive reactions, framing today’s earnings date notice within an established communications cadence.
AI-generated analysis. How Rhea-AI works. Not financial advice.
STOUGHTON, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report fourth quarter and full-year 2025 financial results before the market opens on Thursday, February 26, 2026. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET.
Conference Call Information
To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q4 2025 Earnings Call.” An audio webcast will be accessible from the Investors section of the Company’s website: www.collegiumpharma.com. The webcast will be available for replay on the Company’s website approximately two hours after the event.
About Collegium Pharmaceutical, Inc.
Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and a rapidly growing neuropsychiatry business driven by Jornay PM®, a differentiated treatment for ADHD. Collegium’s strategy includes growing its commercial portfolio, with Jornay PM as the lead growth driver, and deploying capital in a disciplined manner. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com.
Investor Contacts:
Ian Karp
Head of Investor Relations
ir@collegiumpharma.com
Danielle Jesse
Director, Investor Relations
ir@collegiumpharma.com
Media Contact:
Jessica Cotrone
Senior Vice President, Communications & Corporate Affairs
communications@collegiumpharma.com
